AAPG News & Events

Ascentage Pharma announced that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association, EHA2026. Title: "Efficacy of Olverembatinib in patients with chronic-phase chronic myeloid leukemia." Highlights: This study provided the first evidence that olverembatinib is active in patients with ponatinib- and/or asciminib-resistant CP-CML, including those harboring challenging genotypes such as ASXL1 mutations, highlighting its potential as a treatment option for patients with multi-line TKI-resistant disease. Title: "Updated efficacy and safety of olverembatinib." Highlights: These findings support the potential of olverembatinib to induce durable and deep responses in patients with CP-CML without the T315I mutation whose disease was resistant and/or intolerant to first-line TKI therapy, further supporting its role as a second-line treatment option. Title: "The efficacy and safety of switching to olverembatinib." Highlights: Notably, 78.57% of adverse events related to prior TKI therapy improved after patients switched to olverembatinib. These findings support olverembatinib as a potential standard of care for patients with CML-CP previously treated with at least two TKIs. Title: "Updated results of Polaris-1, a global registrational Phase 3 study." Highlights: These findings suggest that olverembatinib combined with low-intensity chemotherapy may induce rapid, deep, and sustained MRD-negative responses in patients with newly diagnosed Ph+ ALL, while maintaining a favorable safety profile, and provide important evidence supporting its use in the frontline setting. Title: "Safety and preliminary efficacy of olverembatinib." Highlights: These findings support the potential of this chemotherapy-free oral dual-targeted regimen to induce rapid and deep remissions, and may provide a novel treatment option for pediatric patients with R/R Ph+ ALL. Title: "Real-world efficacy and safety of Lisaftoclax."

Ascentage Pharma announced that the Company presented its first dataset of alrizomadlin, an MDM2-p53 inhibitor from the Company's apoptosis-targeted pipeline, as monotherapy or in combination with lisaftoclax in pediatric patients with relapsed/metastatic rhabdomyosarcoma or other soft-tissue sarcomas, in a rapid oral presentation at the 62nd American Society of Clinical Oncology, ASCO, Annual Meeting. Key Highlights: In the monotherapy arm, 1 patient with refractory RMS achieved CR. In the combination arm, among 17 response-evaluable pediatric patients with relapsed/refractory solid tumors, the ORR was 23.5%, including 1 CR in a patient with EWS, as well as PRs in 2 patients with RMS and 1 patient with NB. The disease control rate was 70.6%. The regimen demonstrated a manageable safety profile and preliminary antitumor activity in pediatric solid tumors, supporting further investigation